Endpoints News launched Endpoints Signal, an intelligence platform led by Tom Randall, and published the inaugural Biopharma Sentiment Index (BPSI) for Q4 2025. The BPSI scored 78—well below a neutral 100—signaling persistent pessimism across biopharma while flagging ‘‘pockets of hope’’ in parts of the ecosystem. Signal’s analysis combines structured reader surveys with market data to quantify views on business conditions, financing, regulation, and hiring. The report draws from 1,457 verified respondents and will publish quarterly to track sentiment shifts and pulse topics such as M&A outlook and AI adoption.